Scientists Identify Receptor for Papillomavirus

Publication
Article
OncologyONCOLOGY Vol 11 No 5
Volume 11
Issue 5

Researchers at the University of Queensland, Australia, have identified the receptor on human skin and mucosal cells that they believe allows papillomaviruses to attach to and infect those cells.

Researchers at the University of Queensland, Australia, have identifiedthe receptor on human skin and mucosal cells that they believe allows papillomavirusesto attach to and infect those cells.

Human papillomaviruses are responsible for a variety of warts in humans,including skin, foot, laryngopharyngeal, and some types of genital warts.They are also considered to be a major risk factor for the developmentof certain types of cancer.

In the study, reported in the March issue of the Journal of Virology,researchers investigated the interaction of papillomavirus-like particles(VLPs) with two epithelial cell lines. Using a number of different assays,they found that alpha-6-integrin can interact with VLPs, suggesting thatit may function as a cellular receptor for papillomaviruses.

Papillomavirus infects only skin and mucosal surfaces, and this restrictionis thought to be mediated by interactions of the virus with host cell factors.In general, the first step in infection with a crystalline virus is attachmentof the virus to a specific receptor on the surface of the susceptible hostcell. Until now, the receptor for papillomavirus had yet to be found.

"Identification of a receptor for PV [papillomavirus] particlesshould lead to identification of residues on the PV particle that are criticalfor PV binding and uptake and may allow a rational approach to design ofdrugs to inhibit the process of PV infection," say the researchers.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content